DSIP with selank and epitalon
Delta sleep-inducing peptide with selank and epitalon (sleep blend)
Written by Aaron CuhaReviewed Sep 2026
Also known as: Sleep peptide blend, DSIP sleep stack
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
A sleep blend, usually 2 mg DSIP, 2 mg epitalon and 0.5 mg selank. Only one of the three has any sleep evidence, and it is from the 1980s. Nobody has repeated it since.
What people take it for
- Falling asleep faster.
- Staying asleep.
- Fixing a broken body clock.
- Winding down at night.
What the trials actually showed
The blend has never been tested. DSIP has two human sleep studies. One was a 1981 report in the Lancet saying it improved sleep in people with insomnia. The other was a 1987 controlled study of sleep and waking across 24 hours in people with severe long term insomnia. That is the whole file, and it is forty years old. Sleep research has changed completely since then and nobody has tried to repeat it. Epitalon has no controlled human sleep trial at all. Its human record is Russian anti aging work, not sleep. It is in here because of the pineal gland link. Selank does have a trial, for anxiety: 62 people, about as good as a standard anxiety drug. That same trial also reported that selank picks people up. Now the math. The two parts with no modern sleep evidence make up 89 percent of the peptide. The one part with a real trial is 11 percent, and its trial says it is stimulating.
What people report
Reports, not trial results
The good
- Falling asleep faster and waking up less. This is the main report.
- Very vivid dreams.
The bad
- Grogginess the next morning in some people.
- Nothing at all, reported often.
- Feeling wired instead of sleepy in a few people, which fits what the selank trial found.
- Sleep is the easiest thing to fool yourself about. Paying attention to it changes how you rate it.
Where these come from: Peptide and nootropic forums plus seller pages. People talking. The stimulating effect is the one item here that also shows up in a real trial.
My bottom line
The DSIP evidence is not missing, it is frozen. Positive in 1981 and 1987 and never tried again, most likely because nobody can own the result. That is a reason to be curious, not a reason to buy a three part vial where the stimulant is the only part with a real trial.
An opinion, not a finding. I am a coach, not a doctor.
Overview
A sleep and circadian blend, commonly 2 mg DSIP, 2 mg epitalon and 0.5 mg selank, so the two milligram-scale components are four times the third by mass. The human sleep evidence for DSIP is from the early 1980s and has never been replicated in a modern controlled trial, epitalon's human file is a Russian geroprotection tradition rather than sleep research, and the combination has never been studied.
The three components here are sold as a circadian package: one to induce sleep, one to reset the pineal clock, one to take the edge off. Only one of the three has anything resembling sleep evidence, and it is forty years old.
Delta sleep-inducing peptide was reported in a 1981 Lancet paper as improving sleep in insomniacs, and a 1987 study examined its effects on 24 hour sleep-wake behaviour in severe chronic insomnia. Those are the papers the modern product rests on. They are small, they predate modern polysomnographic standards and trial reporting, and no contemporary randomised controlled trial has repeated them. That is a very unusual evidence profile: not absent, but frozen.
Epitalon is a pineal tetrapeptide from the Khavinson bioregulator programme. Its published literature is mostly Russian, mostly about aging and telomeres rather than sleep, and a 2025 review summarises the claimed properties without a modern controlled human trial to anchor them. Its presence in a sleep blend comes from the pineal association with melatonin rather than from any trial showing it changes sleep.
Selank is the third component and has the best clinical file of the three, in anxiety rather than sleep: 62 patients with generalised anxiety disorder and neurasthenia, anxiolytic effects similar to medazepam, plus antiasthenic and psychostimulant effects. That last property is worth noticing on a sleep product. The trial describing selank explicitly reports psychostimulant effects, and it is in a blend sold to help people sleep.
The arithmetic on the common 2 plus 2 plus 0.5 mg formulation: 4.5 mg of total peptide, DSIP and epitalon at 44.4% each and selank at 11.1%. The two components with the weakest sleep evidence are 89% of the peptide mass, and the component with an actual clinical trial behind it is the smallest share and is documented as stimulating.
Mechanism of action
DSIP is a nonapeptide isolated from rabbit cerebral venous blood during sleep induction experiments; its mechanism in people is not established and its clearance is rapid. Epitalon is a tetrapeptide from the pineal bioregulator programme, claimed to act on pineal function and telomerase, mostly on the basis of cell and Russian clinical work. Selank is a tuftsin analogue with anxiolytic activity linked to enkephalin metabolism. No published work describes the three together or any interaction between them.
Human evidence
The sleep evidence is two studies from the 1980s for one component. The other two components have human data for other things, one of which is stimulation.
- The blend: no published study, no registered trial.
- DSIP: a 1981 Lancet report and a 1987 controlled study of 24 hour sleep-wake behaviour in severe chronic insomnia. No modern replication.
- Selank: 62 patients, anxiolytic effects comparable to medazepam, with reported psychostimulant effects.
- Epitalon: no controlled human sleep trial. Its human file is the Russian geroprotection literature.
What this does not tell you: Two forty-year-old studies are not a current evidence base. Sleep research standards, measurement and reporting have all changed beyond recognition since, and the absence of any modern attempt to replicate is itself informative.
What it has been measured to do
Measured in people
Goals DSIP with selank and epitalon has been measured for in a human being, most people first. Counts come from the study lines on this page and deliberately undercount.
- Mood and anxiety62 people · 1 study
What people using it report
Uncontrolled and self-selected, so it cannot show that anything works. It is still the best guide on this page to what people actually do with DSIP with selank and epitalon, what they expect, and what goes wrong. The full account, including the negative reports, is below.
35 of the 36 indexed goals have no study of any kind behind DSIP with selank and epitalon
No trial, no animal work, no cell work on this page reports a result for these. That is an absence of evidence rather than evidence of absence, but it does mean anything you have been told about DSIP with selank and epitalon and one of these did not come from a study cited here.
Reading the research record
The interesting question about DSIP is why nobody repeated the work. The 1980s studies were positive, the peptide is cheap and unpatentable, and forty years passed. The most likely explanation is the one that applies across this database: nobody could own the result, so nobody funded the trial. That is an economic fact about the molecule rather than a verdict on it, and it leaves a buyer with evidence that cannot be checked against modern standards.
The blend's own composition is the second issue. Eighty nine percent of the peptide mass is the two components with no modern sleep evidence, and the remaining eleven percent is the one component with a real clinical trial, whose trial reported psychostimulant effects. A product assembled the other way round would be easier to defend.
Sleep is also a domain where uncontrolled reports are particularly weak, because expectation, routine change and the act of paying attention to sleep all move subjective sleep quality substantially.
The evidence, charted
Fig. 1a · evidence scale
62people, across 1 human study cited here
- 2008 · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova62100%
The whole total is one study of 62. Counts are the enrollment each human citation on this page states, which includes observational cohorts where nobody was given the compound. 2 further human citations state no participant count and are not counted here. Studies still recruiting are excluded, and only studies cited on this page are counted.
Fig. 1b · evidence mix
3 of 4 citations here are human work, the rest is not.
- Human · given to people375%
- Review · summarises other work125%
Counted from the citation list on this page, typed as this page types it. It understates any literature larger than the sources we cite, and a review counts once however many studies it covers.
Fig. 2 · evidence over time
Evidence spans 4 distinct years, 1981 to 2025, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 5 · molecular identity
- Modality
- Blend
- Molecular weight
- Not on file
- Half-life
- Stated in words, not a number
- Sequence length
- None on file
see the exact wording below
Half-life as stated on file: Not defined for the blend. DSIP is described as clearing rapidly and no pharmacokinetic study of the mixture exists.
No amino acid sequence is on file for DSIP with selank and epitalon, which is expected: a blend is not built from residues.
Fig. 6 · what is in the vial
44.4%of a 4.5 mg DSIP with selank and epitalon vial is DSIP
Label mass from a standard vial, not a dose, and not an assay. The ratio is fixed by the seller, so a draw that hits the amount you want of one component sets the amount of every other component with it. No study has tested this combination in any species.
Key studies & citations
- Human1981
Synthetic delta-sleep-inducing peptide improves sleep in insomniacs
The 1981 Lancet report from Schneider-Helmert and colleagues that established the sleep claim for synthetic DSIP in insomniacs, indexed by PubMed as a randomised clinical trial published as a letter. It is the origin of every sleep claim made for this peptide and it has not been replicated in a modern controlled trial.
The Lancet - Human1987
Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia
A controlled clinical trial examining DSIP across 24 hour sleep-wake behaviour in severe chronic insomnia, the most detailed of the 1980s DSIP sleep studies. Along with the 1981 Lancet report it is the whole of the human sleep record for this peptide, and nothing comparable has been published since.
European Neurology - Human2008
[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]
62 patients with generalised anxiety disorder and neurasthenia, 30 on selank against 32 on medazepam. Anxiolytic effects were similar between the two drugs, and selank additionally showed antiasthenic and psychostimulant effects. The psychostimulant finding is worth noting in a product sold for sleep.
Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova - Review2025
Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties
A review of the claimed properties of the pineal tetrapeptide epitalon, drawing largely on cell work and the Russian bioregulator literature. It is a summary of claims rather than a report of a controlled human trial, and it is not a sleep study.
International Journal of Molecular Sciences
What users report
Self-reported experiences, not evidence. Nothing below was measured under controlled conditions, and reports like these cannot separate a real effect from placebo, from the training or diet change that accompanied it, or from what the product actually contained. They are here because knowing what people describe, including what goes wrong, is worth reading alongside the studies.
- Falling asleep faster and waking less, the most common report and the reason people buy it.
- Very vivid dreams.
- Grogginess the next morning in some people and none in others.
- Nothing at all, reported often.
- Feeling wired rather than sleepy, which a minority report and which is consistent with the psychostimulant effects described in the selank trial.
Sources: Peptide and nootropic forums including r/peptides, and vendor pages. Uncontrolled self-reports. The psychostimulant observation is the one item here that also appears in a controlled trial, for the selank component.
Frequently asked questions
Is DSIP proven to work for sleep?
It has a 1981 Lancet report and a 1987 controlled study in severe chronic insomnia, and nothing since. That is not nothing, and it is also not a current evidence base by any modern standard.
Why is there no recent research?
The most likely reason is that the peptide is unpatentable, so no sponsor has a commercial reason to fund a trial. That is an economic fact about the molecule, not a finding about whether it works.
Does epitalon help sleep?
No controlled human trial has tested that. Its human literature is the Russian geroprotection tradition, and its presence in a sleep blend comes from the pineal association rather than from sleep data.
Why is a stimulating peptide in a sleep blend?
That is a fair question. The trial describing selank reported antiasthenic and psychostimulant effects alongside its anxiolytic ones. It is the smallest component by mass at about a ninth of the peptide, but it is the one with the clearest clinical file.
What is the split?
Commonly 2 mg DSIP, 2 mg epitalon and 0.5 mg selank, which is 4.5 mg of peptide with the first two at 44.4% each and selank at 11.1%.